Objective To summarize the clinical characteristics and nutrition therapy for children with lysinuric protein intolerance (LPI). Methods The clinical manifestations, laboratory test results and enteral nutrition treatment in a girl with LPI diagnosed in Xiangya Hospital, Central South University were retrospective analyzed. Additionally, the data of the children with LPI reported in China and overseas were reviewed. Results A case of 4-year-old girl was presented, who exhibited significant gastrointestinal symptoms, such as chronic abdominal distension, prolonged diarrhea, recurrent pneumonia, and limited growth. She had a poor response to anti-infection treatment. After receiving enteral nutrition therapy, she did not experience any gastrointestinal discomfort, and there were improvements in the levels of hemoglobin, albumin, and blood ammonia. Unfortunately, due to serious illness, she declined further treatment and later passed away. A total of 92 cases of pediatric patients with LPI have been reported to date, including one case reported in this study. Most children with LPI experienced disease onset after weaning or introduction of complementary foods, presenting with severe digestive system symptoms, malnutrition, and growth retardation. It is noteworthy that only 50% (46/92) of these cases received nutritional therapy, which effectively improved their nutritional status. Among the 92 children, 8 (9%) died, and long-term follow-up data were lacking in other reports. Conclusions LPI often involves the digestive system and may result in growth restriction with a poor prognosis. Nutritional therapy plays a crucial role in the comprehensive treatment of LPI.
Key words
Lysinuric protein intolerance /
Malnutrition /
Nutrition therapy /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
1 Rotoli BM, Barilli A, Visigalli R, et al. y+LAT1 and y+LAT2 contribution to arginine uptake in different human cell models: implications in the pathophysiology of lysinuric protein intolerance[J]. J Cell Mol Med, 2020, 24(1): 921-929. PMID: 31705628. PMCID: PMC6933409. DOI: 10.1111/jcmm.14801.
2 Noguchi A, Nakamura K, Murayama K, et al. Clinical and genetic features of lysinuric protein intolerance in Japan[J]. Pediatr Int, 2016, 58(10): 979-983. PMID: 26865117. DOI: 10.1111/ped.12946.
3 Noguchi A, Takahashi T. Overview of symptoms and treatment for lysinuric protein intolerance[J]. J Hum Genet, 2019, 64(9): 849-858. PMID: 31213652. DOI: 10.1038/s10038-019-0620-6.
4 Mauhin W, Habarou F, Gobin S, et al. Update on lysinuric protein intolerance, a multi-faceted disease retrospective cohort analysis from birth to adulthood[J]. Orphanet J Rare Dis, 2017, 12(1): 3. PMID: 28057010. PMCID: PMC5217205. DOI: 10.1186/s13023-016-0550-8.
5 Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424. PMID: 25741868. PMCID: PMC4544753. DOI: 10.1038/gim.2015.30.
6 杨琴, 马红玲, 郑跃杰. 以肺间质疾病为主要表现的赖氨酸尿性蛋白耐受不良一例[J]. 中华儿科杂志, 2019, 57(1): 60-62. PMID: 30630234. DOI: 10.3760/cma.j.issn.0578-1310.2019.01.014.
7 Kang E, Kim T, Oh A, et al. Lysinuric protein intolerance with homozygous SLC7A7 mutation caused by maternal uniparental isodisomy of chromosome 14[J]. J Hum Genet, 2019, 64(11): 1137-1140. PMID: 31427715. DOI: 10.1038/s10038-019-0657-6.
8 Unal O, Co?kun T, Orhan D, et al. Pregnancy and lactation outcomes in a Turkish patient with lysinuric protein intolerance[J]. JIMD Rep, 2014, 13: 33-36. PMID: 24142278. PMCID: PMC4110330. DOI: 10.1007/8904_2013_259.
9 Kurko J, Tringham M, Tanner L, et al. Imbalance of plasma amino acids, metabolites and lipids in patients with lysinuric protein intolerance (LPI)[J]. Metabolism, 2016, 65(9): 1361-1375. PMID: 27506743. DOI: 10.1016/j.metabol.2016.05.012.
10 Alqarajeh F, Omorodion J, Bosfield K, et al. Lysinuric protein intolerance: pearls to detect this otherwise easily missed diagnosis[J]. Transl Sci Rare Dis, 2020, 5(1-2): 81-86. PMID: 33134088. PMCID: PMC7590902. DOI: 10.3233/TRD-190035.
11 Contreras JL, Ladino MA, Aránguiz K, et al. Immune dysregulation mimicking systemic lupus erythematosus in a patient with lysinuric protein intolerance: case report and review of the literature[J]. Front Pediatr, 2021, 9: 673957. PMID: 34095032. PMCID: PMC8172984. DOI: 10.3389/fped.2021.673957.
12 Valimahamed-Mitha S, Berteloot L, Ducoin H, et al. Lung involvement in children with lysinuric protein intolerance[J]. J Inherit Metab Dis, 2015, 38(2): 257-263. PMID: 25335805. DOI: 10.1007/s10545-014-9777-5.
13 Tanner LM, N?nt?-Salonen K, Venetoklis J, et al. Nutrient intake in lysinuric protein intolerance[J]. J Inherit Metab Dis, 2007, 30(5): 716-721. PMID: 17588131. DOI: 10.1007/s10545-007-0558-2.
14 崔冬, 胡宇慧, 唐根, 等. 3例赖氨酸尿性蛋白耐受不良患儿的临床特点及SLC7A7基因突变分析[J]. 中国当代儿科杂志, 2019, 21(4): 375-380. PMID: 31014432. PMCID: PMC7389226. DOI: 10.7499/j.issn.1008-8830.2019.04.014.
15 Miko?ajek-Bedner W, Torbé A, Kwiatkowski S, et al. Pregnancy delivery and puerperium in a patient with lysinuric protein intolerance: a case report[J]. Ginekol Pol, 2013, 84(7): 654-656. PMID: 24032281. DOI: 10.17772/gp/1621.
16 彭方, 陆珺, 张祥, 等. 赖氨酸尿性蛋白耐受不良一例[J]. 中华神经科杂志, 2016, 49(11): 874-876. DOI: 10.3760/cma.j.issn.1006-7876.2016.11.010.
17 Ogier de Baulny H, Schiff M, Dionisi-Vici C. Lysinuric protein intolerance (LPI): a multi organ disease by far more complex than a classic urea cycle disorder[J]. Mol Genet Metab, 2012, 106(1): 12-17. PMID: 22402328. DOI: 10.1016/j.ymgme.2012.02.010.
18 Rajantie J, Simell O, Rapola J, et al. Lysinuric protein intolerance: a two-year trial of dietary supplementation therapy with citrulline and lysine[J]. J Pediatr, 1980, 97(6): 927-932. PMID: 6777479. DOI: 10.1016/s0022-3476(80)80422-7.
19 Awrich AE, Stackhouse WJ, Cantrell JE, et al. Hyperdibasicaminoaciduria, hyperammonemia, and growth retardation: treatment with arginine, lysine, and citrulline[J]. J Pediatr, 1975, 87(5): 731-738. PMID: 1185337. DOI: 10.1016/s0022-3476(75)80296-4.
20 Barilli A, Rotoli BM, Visigalli R, et al. Impaired phagocytosis in macrophages from patients affected by lysinuric protein intolerance[J]. Mol Genet Metab, 2012, 105(4): 585-589. PMID: 22325938. DOI: 10.1016/j.ymgme.2012.01.008.
21 Esposito V, Lettiero T, Fecarotta S, et al. Growth hormone deficiency in a patient with lysinuric protein intolerance[J]. Eur J Pediatr, 2006, 165(11): 763-766. PMID: 16775724. DOI: 10.1007/s00431-006-0170-8.
22 Niinikoski H, Lapatto R, Nuutinen M, et al. Growth hormone therapy is safe and effective in patients with lysinuric protein intolerance[J]. JIMD Rep, 2011, 1: 43-47. PMID: 23430827. PMCID: PMC3509816. DOI: 10.1007/8904_2011_15.
23 Evelina M, Grazia M, Francesca O, et al. Growth hormone deficiency and lysinuric protein intolerance: case report and review of the literature[J]. JIMD Rep, 2015, 19: 35-41. PMID: 25614305. PMCID: PMC4501240. DOI: 10.1007/8904_2014_362.
PDF(598 KB)
